| Y-mAbs and Nobelpharma Announce Exclusive License and Distribution Agreement for DANYELZA® (naxitamab-gqgk) in Japan | 11/04 07:35 | globenewswire.com |
| Will Y-mAbs Therapeutics, Inc. (YMAB) Report Negative Earnings Next Week? What You Should Know | 11/01 11:06 | zacks.com |
| Y-mAbs Announces Third Quarter 2024 Conference Call and Webcast | 10/25 07:05 | globenewswire.com |
| Y-mAbs to Participate in Upcoming Investor Conferences in October | 10/01 07:05 | globenewswire.com |
| Y-mAbs Presents Neuroblastoma Research on Naxitamab and SADA PRIT Technology Platform at AACR Special Conference on Advances in Pediatric Cancer Research | 09/06 07:30 | globenewswire.com |
| Y-mAbs to Participate in Upcoming Investor Conferences in September | 09/03 08:32 | globenewswire.com |
| Why Y-mAbs Therapeutics Stock Got Mashed on Monday | 08/12 18:33 | fool.com |
| Revisiting Y-mAbs After The Summer Oncology Meeting (Rating Upgrade) | 08/12 12:08 | seekingalpha.com |
| Y-mAbs Therapeutics, Inc. (YMAB) Q2 2024 Earnings Call Transcript | 08/12 11:20 | seekingalpha.com |
| Y-mAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Misses Revenue Estimates | 08/12 08:40 | zacks.com |